Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

J. Miao, Y. Jin, R. L. Marunde, S. Kim, Sara Quinney, Milan Radovich, L. Li, S. D. Hall

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The genes that encode for CYP3A4 and CYP3A5 are located in the same region (CYP3A cluster) on chromosome 7. Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. We hypothesize that MDZ disposition in vivo is associated with genotypes of the CYP3A cluster. A meta-analysis of the pharmacokinetic (PK) parameters from seven clinical trials was carried out, in which MDZ was administered both intravenously and orally. DNA samples were available from 116 patients. There were significant ethnic differences in the allelic frequencies of these four common single-nucleotide polymorphisms (SNPs) in the CYP3A cluster. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians, and between CYP3A5*1 and CYP3A4*1B in African Americans. There were no differences in MDZ disposition in vivo between different genotypes, haplotypes and diplotypes in the CYP3A cluster (P>0.05). No significant differences in MDZ PK parameters were observed between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not observed between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The rGC's of MDZ PK parameters were between 0.3 and 13.6%. In conclusion, the meta-analysis of seven studies suggests that environmental factors explain the majority of CYP3A activity variation. Further studies are necessary to define the functional significance of SNPs in the CYP3A cluster and the effects of CYP3A genotypes on MDZ disposition in vivo.

Original languageEnglish
Pages (from-to)319-326
Number of pages8
JournalPharmacogenomics Journal
Volume9
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Genotype
Pharmacokinetics
African Americans
Single Nucleotide Polymorphism
Meta-Analysis
Chromosomes, Human, Pair 7
Linkage Disequilibrium

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. / Miao, J.; Jin, Y.; Marunde, R. L.; Kim, S.; Quinney, Sara; Radovich, Milan; Li, L.; Hall, S. D.

In: Pharmacogenomics Journal, Vol. 9, No. 5, 2009, p. 319-326.

Research output: Contribution to journalArticle

Miao, J. ; Jin, Y. ; Marunde, R. L. ; Kim, S. ; Quinney, Sara ; Radovich, Milan ; Li, L. ; Hall, S. D. / Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. In: Pharmacogenomics Journal. 2009 ; Vol. 9, No. 5. pp. 319-326.
@article{d7fa7140f64e45afa5c48b8676662ecc,
title = "Association of genotypes of the CYP3A cluster with midazolam disposition in vivo",
abstract = "The genes that encode for CYP3A4 and CYP3A5 are located in the same region (CYP3A cluster) on chromosome 7. Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. We hypothesize that MDZ disposition in vivo is associated with genotypes of the CYP3A cluster. A meta-analysis of the pharmacokinetic (PK) parameters from seven clinical trials was carried out, in which MDZ was administered both intravenously and orally. DNA samples were available from 116 patients. There were significant ethnic differences in the allelic frequencies of these four common single-nucleotide polymorphisms (SNPs) in the CYP3A cluster. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians, and between CYP3A5*1 and CYP3A4*1B in African Americans. There were no differences in MDZ disposition in vivo between different genotypes, haplotypes and diplotypes in the CYP3A cluster (P>0.05). No significant differences in MDZ PK parameters were observed between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not observed between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The rGC's of MDZ PK parameters were between 0.3 and 13.6{\%}. In conclusion, the meta-analysis of seven studies suggests that environmental factors explain the majority of CYP3A activity variation. Further studies are necessary to define the functional significance of SNPs in the CYP3A cluster and the effects of CYP3A genotypes on MDZ disposition in vivo.",
author = "J. Miao and Y. Jin and Marunde, {R. L.} and S. Kim and Sara Quinney and Milan Radovich and L. Li and Hall, {S. D.}",
year = "2009",
doi = "10.1038/tpj.2009.21",
language = "English",
volume = "9",
pages = "319--326",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

AU - Miao, J.

AU - Jin, Y.

AU - Marunde, R. L.

AU - Kim, S.

AU - Quinney, Sara

AU - Radovich, Milan

AU - Li, L.

AU - Hall, S. D.

PY - 2009

Y1 - 2009

N2 - The genes that encode for CYP3A4 and CYP3A5 are located in the same region (CYP3A cluster) on chromosome 7. Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. We hypothesize that MDZ disposition in vivo is associated with genotypes of the CYP3A cluster. A meta-analysis of the pharmacokinetic (PK) parameters from seven clinical trials was carried out, in which MDZ was administered both intravenously and orally. DNA samples were available from 116 patients. There were significant ethnic differences in the allelic frequencies of these four common single-nucleotide polymorphisms (SNPs) in the CYP3A cluster. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians, and between CYP3A5*1 and CYP3A4*1B in African Americans. There were no differences in MDZ disposition in vivo between different genotypes, haplotypes and diplotypes in the CYP3A cluster (P>0.05). No significant differences in MDZ PK parameters were observed between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not observed between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The rGC's of MDZ PK parameters were between 0.3 and 13.6%. In conclusion, the meta-analysis of seven studies suggests that environmental factors explain the majority of CYP3A activity variation. Further studies are necessary to define the functional significance of SNPs in the CYP3A cluster and the effects of CYP3A genotypes on MDZ disposition in vivo.

AB - The genes that encode for CYP3A4 and CYP3A5 are located in the same region (CYP3A cluster) on chromosome 7. Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. We hypothesize that MDZ disposition in vivo is associated with genotypes of the CYP3A cluster. A meta-analysis of the pharmacokinetic (PK) parameters from seven clinical trials was carried out, in which MDZ was administered both intravenously and orally. DNA samples were available from 116 patients. There were significant ethnic differences in the allelic frequencies of these four common single-nucleotide polymorphisms (SNPs) in the CYP3A cluster. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians, and between CYP3A5*1 and CYP3A4*1B in African Americans. There were no differences in MDZ disposition in vivo between different genotypes, haplotypes and diplotypes in the CYP3A cluster (P>0.05). No significant differences in MDZ PK parameters were observed between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not observed between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The rGC's of MDZ PK parameters were between 0.3 and 13.6%. In conclusion, the meta-analysis of seven studies suggests that environmental factors explain the majority of CYP3A activity variation. Further studies are necessary to define the functional significance of SNPs in the CYP3A cluster and the effects of CYP3A genotypes on MDZ disposition in vivo.

UR - http://www.scopus.com/inward/record.url?scp=70349664493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349664493&partnerID=8YFLogxK

U2 - 10.1038/tpj.2009.21

DO - 10.1038/tpj.2009.21

M3 - Article

VL - 9

SP - 319

EP - 326

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -